EGFR and pancreatic neoplasm: In T helper 1 cell cytokine‐enriched environments in pancreatic cancer, EGFR‐targeted therapy induced by EGFRBi (EGFR bispecific antibodies) armed active T cells, restraining the prostaglandin‐endoperoxide synthase 2 (PTGS2/COX2)/PGE2/ARG‐1 axis and enhancing TNF‐α, IL‐12, CCL3, CCL4, CCL5, CXCL9, and CXCL10 to suppress MDSC differentiation and accumulation.207